Gefitinib in Pretreated Non–Small-Cell Lung Cancer (NSCLC): Analysis of Efficacy and Correlation With HER2 and Epidermal Growth Factor Receptor Expression in Locally Advanced or Metastatic NSCLC

This publication has 20 references indexed in Scilit:

• Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
  New England Journal of Medicine, 2002
• Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group Trial
  Journal of Clinical Oncology, 2001
• Objective regressions in non-small cell lung cancer patients treated in Phase I trials of oral ZD1839 (IressaTM), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR)
  Lung Cancer, 2000
• New Guidelines to Evaluate the Response to Treatment in Solid Tumors
  JNCI Journal of the National Cancer Institute, 2000
• Gemcitabine and Cisplatin Versus Mitomycin, Ifosfamide, and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Randomized Phase III Study of the Italian Lung Cancer Project
  Journal of Clinical Oncology, 1999
• Epidermal Growth Factor Receptor Inhibition in Cancer Therapy: Biology, Rationale and Preliminary Clinical Results
  Investigational New Drugs, 1999
• Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers
  The EMBO Journal, 1998
• A Hierarchical Network of Interreceptor Interactions Determines Signal Transduction by Neu Differentiation Factor/Neuregulin and Epidermal Growth Factor
  Molecular and Cellular Biology, 1996
• GROWTH FACTOR RECEPTOR TYROSINE KINASES
  Annual Review of Biochemistry, 1988
• Epidermal Growth Factor
  Annual Review of Biochemistry, 1979